Q&A: Forthcoming trial will examine drug’s ‘great potential’ in long COVID

Q&A: Forthcoming trial will examine drug’s ‘great potential’ in long COVID

Axcella Therapeutics announced that it is recruiting for a randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of AXA1125 in patients with exertional fatigue related to long COVID.AXA1125 (Axcella Therapeutics) is an “endogenous metabolic modulator composition of six amino acids and derivatives,” that has shown promise in treating metabolism, inflammation and fibrosis related to non-alcoholic steatohepatitis (NASH), the company said on its website.“With no approved long COVID therapies, the need for continued innovation is urgent,”Read More

Share on facebook
Share on twitter
Share on linkedin